FDA Approves Lucentis Biosimilar Nufymco - Summary - MDSpire
Coming Soon: Introducing MDSpire News. Learn more
Conexiant’s news site is now MDSpire News. Learn more

FDA Approves Lucentis Biosimilar Nufymco

Ranibizumab-leyk (Nufymco) is approved for all Lucentis indications.

  • By

  • mdspire news news staff

  • January 2, 2026

  • 1 min

Share

Objective:

To announce the FDA approval of Nufymco, a biosimilar of Lucentis, for various ophthalmic conditions.

Approach:
    Key Findings:
    • Nufymco is a biosimilar of Lucentis.
    • FDA approval covers multiple ophthalmic conditions.
    • Zydus Lifesciences will handle marketing in the US.
    Interpretation:

    The approval of Nufymco represents a significant advancement in the availability of affordable treatment options for patients with serious eye conditions, enhancing access to care.

    Conclusion:

    The approval of Nufymco highlights Bioeq's commitment, alongside its partners, to expanding access to high-quality biosimilars in the ophthalmic field.

Original Source(s)

FDA Approves Lucentis Biosimilar Nufymco

  • by mdspire news news staff

  • January 2, 2026

Related Content

Medical Oddities: The Economics of Shut-Eye

Sleep became a commodity, tea became a therapy, and cats got a reprieve this week.

Glycemic variability may signal retinal changes

Greater glucose fluctuations but not HbA1c were associated with neuroretinal alterations over 3 years in pediatric patients with type 1 diabetes.

Calculating the Myopic Nerve

Two-Continent Eye Study offers a risk-score approach for high myopia-associated optic neuropathies

  • August 25, 2026

  • 3 min